The Pharma Data

DECEMBER 17, 2020

In preclinical studies, Janux TRACTr drug candidates have demonstrated comparable anti-tumor efficacy relative to standard T cell engagers but lack the associated liabilities related to cytokine release, healthy tissue toxicities, or systemic immune activation, the company said. “At Janux, in exchange, will receive up to $500.5

Immune Response

Broad Institute

JUNE 14, 2023

Glimcher is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research. Beering Award for outstanding research contributions to advancement of biomedical or clinical science; and the L'Oréal-UNESCO Award for Women in Science. She has also received the 2017 George M.

Medical Schools

Drug Target Review

FEBRUARY 28, 2024

Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers. Mr Ho has worked in the biotechnology industry for almost 20 years.

Therapies

The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. We are encouraged by the high level of neutralizing antibodies in combination with the strong Th1 response which we believe could play an important role in controlling infection. About Clover Biopharmaceuticals.

Vaccine

Drug Target Review

APRIL 3, 2024

Could you share an example of a specific project or research that you have worked on and the impact it has had in your field? We continue our research to gain further insights into the underlying biology of GDF-15 and its role in cancer pathogenesis and treatment resistance. in North America) in late 2017.

Science

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. Dynavax is also advancing CpG 1018 as an advanced vaccine adjuvant through research collaborations and partnerships. CHENGDU, China , Feb.

Clinical Trials

The Pharma Data

JANUARY 31, 2021

Clover’s S-Trimer antigen adjuvanted with CpG 1018 plus alum demonstrated low reactogenicity while providing high levels of neutralizing antibodies and a strong Th1-biased cell-mediated immune response. Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.

Vaccine

The Pharma Data

DECEMBER 15, 2020

However, if the immune system malfunctions, it can attack healthy cells, tissues and organs. Researchers are aware of more than 80 diseases that occur when the immune system attacks the body’s own organs, tissues and cells. The human monoclonal antibody targets specific immune plasma cells. New Immune System Cell.

Disease

Drug Target Review

DECEMBER 5, 2024

Among them, adeno-associated viruses (AAVs) stand out due to their small size, high efficiency in gene delivery, low immunogenicity, and potential for customisable tissue targeting, making them the leading tool in gene expression research.

Therapies

The Pharma Data

NOVEMBER 10, 2020

This potentially ground-breaking approach for immunotherapies originated in my laboratory and was subsequently reported by other researchers in the field.”. Recently, we also successfully demonstrated that nasally administered Foralumab is not only well-tolerated, but also produced desirable immunological responses. da Cunha, A.

Clinical Trials

The Pharma Data

NOVEMBER 9, 2020

executive vice president of Research and Development at Amgen. Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma.

Trials

The Pharma Data

DECEMBER 21, 2020

executive vice president of Research and Development at Amgen. Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma.

Trials

Broad Institute

OCTOBER 11, 2023

Manguso, who’d recently graduated from college and was conducting research at the University of Copenhagen as a Fulbright scholar, moved back to the Boston area to be with his mother as she underwent treatment. They are used to treat cancers including melanoma and non-small cell lung cancer, but work only for a small fraction of patients.

Research

Drug Target Review

OCTOBER 26, 2023

Alipogene tiparvovec and voretigene neparvovec-rzyl, two recombinant AAV-based gene therapy products, were approved by the European Medicines Agency (EMA) to treat lipoprotein lipase deficiency in 2012 2 and by the US Food and Drug Administration (FDA) to treat inherited retinal dystrophy in 2017, respectively.

Engineering

Drug Target Review

OCTOBER 2, 2024

Early-phase clinical trials have shown the safety and efficacy of using stem cells for cardiac repair, encouraging further research and development. While commonly used, AAVs have limitations, including immune reactions and difficulties with re-dosing due to pre-existing antibodies. 2017 May 31;58(3):435-440. Epub 2017 May 23.

Therapies

The Pharma Data

APRIL 8, 2022

Now, new research from the Wyss Institute at Harvard University has revealed that this constant pattern of stretching and relaxing does even more – it generates immune responses against invading viruses. a Wyss Technology Development Fellow at the Institute. ” The results are published today in Nature Communications.

Virus

PerkinElmer

AUGUST 25, 2019

1 AlphaLISA ® Assay Technology Studies done using human tumor cell lines by PerkinElmer Application Scientist Jeanine Hinterneder have contributed to our understanding of how tumor cells develop the ability to evade the immune response. When that occurs the cancer becomes more severe.

Protein Expression

PLOS: DNA Science

OCTOBER 12, 2023

Can they deliver healing genes without triggering an overactive immune response? The details are disturbingly reminiscent of the famous case of Jesse Gelsinger , who died from a ferocious immune response to experimental gene therapy in September 1999. An immune response is two-tiered.

Therapies

The Pharma Data

SEPTEMBER 10, 2021

Imfinzi (durvalumab) is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses. Since the first approval in May 2017, more than 100,000 patients have been treated with Imfinzi.

Treatment

The Pharma Data

JUNE 18, 2021

Senior Vice President and Head of Vaccine Research & Development, Pfizer. With a single injection, PREVNAR 20 provides adults with strong and meaningful protection against serotypes responsible for the majority of circulating pneumococcal disease around the world.”. Jansen, Ph.D., IMPORTANT SAFETY INFORMATION.

Vaccine

The Pharma Data

NOVEMBER 1, 2020

This clinical trial will be coordinated by the team at the INTRIALS, a leading, full-service Latin America Clinical Research Organization (CRO), based in Sao Paulo City, Brazil. The clinical data from this trial is expected to available by the end of this year. Brazil has reported almost 5.5M

Clinical Trials

The Pharma Data

MARCH 16, 2021

Vice President, Rheumatology Disease Area Leader, Janssen Research & Development, LLC. for the treatment of adults with moderate to severe plaque PsO in July 2017 and in July 2020 for adults with active PsA. TREMFYA was approved in the U.S. 4,5 Complete study results were previously published in The Lancet.

Treatment

The Pharma Data

MARCH 11, 2021

In 2017, Opdivo was granted accelerated approval by the FDA as a single agent for patients with HCC who have been previously treated with sorafenib. The accelerated approval was based on tumor responses from the Phase 1/2 CheckMate -040 trial. About Opdivo.

Treatment

The Pharma Data

OCTOBER 28, 2020

Adults with COVID-19 ARDS As cases of COVID-19 surge in the United States and globally, deaths continue to increase from ARDS in ventilator-dependent patients as a result of an overactive immune response in the lungs to COVID-19. Research and Development payments were US$9.9 In addition, $5.2 TEMCELL ® HS Inj.

Treatment

The Pharma Data

APRIL 7, 2023

Imfinzi Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses.

Trials

The Pharma Data

JULY 23, 2021

Opdivo was first granted this indication in 2017 under the FDA’s accelerated approval program, making it the first immunotherapy agent to be approved for use in this setting. The accelerated approval was based on tumor responses from the Phase 1/2 CheckMate -040 trial. About Opdivo.

Treatment

Drug Target Review

OCTOBER 4, 2023

The research community pressed on, turning to novel compounds that were substantially more potent than those used in the first generation. Associating immunomodulatory and cytotoxic payloads on the same ADC could also amplify the therapeutic effect of cytotoxic payloads harnessing the power of the immune system to target tumour cells.

Small Molecule

The Pharma Data

SEPTEMBER 15, 2020

I am proud of the truly transformational science that our research and clinical teams are bringing to the fight against disease, as well as the unprecedented speed with which we are advancing our clinical programs in the battle against COVID-19. THERAPEUTIC AREAS OF FOCUS.

Vaccine

Drug Target Review

JANUARY 15, 2024

Our innate immune system evolved to clear genetically diverse pathogens and limit host toxicity, raising the possibility that it can produce similar effects in cancer. What aspects prompted this research direction? The preclinical results demonstrated significant immune responses and tumour regression.

Treatment

The Pharma Data

AUGUST 22, 2021

More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination. 2017; 61(3): e01714-16. The primary analysis was based on 5,172 participants who did not have SARS-CoV-2 infection at baseline. Antimicrob Agents Chemother. Yu XQ, et al.

Trials

Drug Target Review

FEBRUARY 25, 2025

Dr Jonathan Zalevsky, the companys chief research & development officer, has played a pivotal role in driving the development of NKTR-255. With over 20 years of experience in the biopharmaceutical industry, particularly in oncology and immunology, Zalevskys work has helped shape the companys approach to immune-oncology.

Therapies

Broad Institute

NOVEMBER 6, 2024

By Leah Eisenstadt November 6, 2024 Oncologist Kerry Reynolds (left) and researcher Alexandra-Chloé Villani (right) work together to better understand and treat complications of immunotherapy. Patients can even develop life-threatening organ inflammation after a single dose. How did you go about launching this effort?

Research

Broad Institute

NOVEMBER 6, 2024

By Leah Eisenstadt November 6, 2024 Credit: Ricardo Job-Reese, Broad Communications Despite being one of the rarer complications from immune checkpoint inhibitors, myocarditis is the most deadly. This work provides a biological foundation for testing more targeted therapies for myocarditis due to an immune checkpoint inhibitor.

Immune Response